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Aim: Role of PET-CT in assessment of myocardial viability in patients with LV dysfunction.
Methods: This prospective study included 120 patients with LV dysfunction who underwent
99mTechnetium-Sestamibi myocardial perfusion SPECT-CT and 18FFDG cardiac PET-CT.
They also underwent serial echocardiography and coronary angiography along with myo-
cardial perfusion and FDG PET study.
Results: Thirty-three patients had single vessel disease, 48 had triple vessel disease, and rest
had double vessel disease. Among 786 segments, matched defects were seen in 432 (55%)
and mismatched defects in 354 (45%) segments. 78 patients were surgically managed, and 42
were medically managed. The change in LVEF after surgical management was statistically
signiﬁcant compared to medical management.
Conclusion: Viability assessment should be performed in patients who present after 12 h of
acute myocardial infarction or with LV dysfunction due to ischemic heart disease to decide
upon appropriate surgical management.
# 2015 Cardiological Society of India. Published by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Available online at www.sciencedirect.com
ScienceDirect
journal homepage: www.elsevier.com/locate/ihj1. Introduction
Coronary artery disease (CAD) is one of the leading causes of
morbidity and mortality in India and worldwide. In India, CAD
occurs 5–10 years earlier than in western countries affecting
the working population mainly between 35 and 65 years of
age.1 Various factors such as sedentary lifestyle, dietary
indiscipline, and increase in prevalence of diabetes mellitus* Corresponding author.
E-mail address: drismurthy@gmail.com (I. Sathyamurthy).
1 Formerly fellow in Nuclear Medicine at Apollo Hospital, Chennai, 
http://dx.doi.org/10.1016/j.ihj.2015.11.017
0019-4832/# 2015 Cardiological Society of India. Published by Elsevier 
(http://creativecommons.org/licenses/by-nc-nd/4.0/).(DM) have worsened the situation. Majority of the patients,
who present with features of left ventricular (LV) dysfunction
have ischemic CAD.2 Though our knowledge about the
pathophysiology of CAD has tremendously improved in past
years, still the prognosis remains grave with annual mortality
around 10–15%.3 Since the time Braunwald4 described the
myocardial ischemic process after brief coronary occlusion as
‘‘hit, run and stun’’ and Rahimtoola5 described hibernating
myocardium, the viability assessment plays an important roleIndia.
B.V. This is an open access article under the CC BY-NC-ND license
Table 1 – Patients characteristics (age-wise distribution).
Age (years) <50 51–65 >66
Age (n = 120) 33 60 27
Sex
Male (n = 107) 29 54 2
Female (n = 13) 4 7 2
Diabetes mellitus (n = 71)
Male 17 36 13
Female 3 1 1
Hypertension (n = 64)
Male 12 33 11
Female 2 4 2
Both DM and HTN (n = 40)
Male 8 24 5
Female 2 0 1
History of MI (n = 107)
Male 30 44 21
Female 4 6 2
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viable myocardium, timely coronary reperfusion limits the
progression of myocardial damage and loss of regional
contraction, thereby decreasing morbidity and mortality.
In the present study, F-18 Fluorodeoxyglucose (FDG)
Positron Emission Tomography-Computed Tomography scan
(PET-CT) which is one of the commonly used investigation for
accurate assessment of viable myocardium was used. There
are conﬂicting results regarding viability assessment for
determining whether a particular patient would beneﬁt from
coronary revascularization process or not. The aim of the
present study is to ﬁnd out whether treatment planning based
on viability assessment really beneﬁtted the patients.
2. Materials and methods
The present prospective study was performed at a tertiary
referral hospital in Chennai from Jan 2011 to Dec 2013. All
patients were referred by the cardiologists for viability
assessment. Informed consent was obtained from all the
patients, and ethics committee approval was obtained. Adult
patients, who presented with features of LV dysfunction with
symptoms of shortness of breath, proven myocardial infarc-
tion (MI) but presenting 12 h after onset of symptoms and
those with prior history of MI presenting with new onset of
symptoms related to myocardial ischemia were included in
the study. Patients of MI presenting within 12 h after onset of
symptoms and those with left main CAD by coronary
angiography were excluded from the study.
A total of 120 patients were included in this prospective
study for analysis; of which, 107 were males and 13 were
female, and their average age was 56.8  10.9 years. DM was
present in 71 patients, while hypertension (HTN) in 64 and 40
patients had both DM and HTN. Twenty-ﬁve patients did not
have either of it. ST segment elevation MI (STEMI) was present
in 107 patients, which was proven by either electrocardiogra-
phy (ECG), biochemical parameters or by echocardiography.
Rest 13 patients had evidence of non-STEMI. All patients
underwent echocardiography at the time of presentation and
at 3 months follow-up after PET study. The demographic
parameters are shown in Table 1.
All the patients underwent Technetium-99m Sestamibi
(Tc-99 m MIBI) myocardial SPECT-CT study and F-18 FDG PET-
CT study for myocardial viability apart from echocardiograph-
ic testing after informed consent. Matched defects in both the
studies were considered as scarred tissue. Defects in Tc-99m
MIBI SPECT-CT with mismatched 18F-FDG uptake were
regarded as hibernating but viable myocardium.
2.1. 99mTc-MIBI myocardial SPECT-CT study
Patients presented for SPECT CT study within 2 h fasting and
10 millicurie (mCi) of 99mTc-MIBI was administered intrave-
nously at rest after which patients were asked to have fatty
meal. They were scanned on dual head Siemens Symbia T6
SPECT-CT gamma camera using IQ.SPECT technology after 45–
60 min of injection. The images were acquired in 17 projec-
tions per detector in 2088 acquisition arc with 598 as starting
angle using smartzoom collimators and cardio-centric orbitwith 14 s per projection (total 4 min) coupled with ECG gating.
Smartzoom collimators are special type of collimators that
center on the heart, collecting up to 4 times more counts than
parallel hole collimators. Reconstruction was done using IQ.
SPECT reconstruction algorithm. Quantitative processing was
done on Emory cardiac toolbox.
2.2. 18F-FDG cardiac PET-CT study
The following day after 6 h of fasting, these patients under-
went F-18 FDG cardiac PET-CT study. Depending on blood
glucose level, glucose load or intravenous insulin as per sliding
scale was administered according to standard protocol.6 They
were injected with 5–8 mCi of F-18 FDG when the blood glucose
level was <140 mg/ml. Patients, whose blood glucose level was
more than >140 mg/ml, were rescheduled for subsequent days
after control of blood glucose. Patients were imaged on Philips
Gemini TF64 PET-CT scanner with ECG gating using standard
cardiac protocol after 1 h. The images were reconstructed
using RAMLA reconstruction technique. A cutoff level for FDG
uptake of 50% or greater was considered as positive for viability
as shown by Slart et al.7
2.3. Image analysis
Both SPECT and PET images were loaded on a single Extended
Brilliance Workstation (EBW) platform and analyzed in the
Emory cardiac toolbox by making side-to-side comparison.
Generally '17-segment' model is used for analysis of cardiac
segments in PET and SPECT images. However for simplicity, we
had used 5-segment cardiac model. Accordingly the LV
myocardium was divided into apex, septum, anterior, inferi-
or, and lateral walls in both the studies. The defect and its
extent were analyzed. Defects in both the studies (matched)
were considered as scars. Defects at Tc-99 m MIBI SPECT, but
with 18F-FDG uptake (mismatched), were regarded as hibernat-
ing but viable myocardium. D'Egadio et al.8 showed that when
myocardial viability is more than 7% of LV myocardium, then
patient beneﬁtted with revascularization. A similar criterion
was followed in our study. All patients having myocardial
viability more than 7% underwent revascularization, while
Table 2 – Region wise distribution of matched and
mismatched segments.
Walls Study
99mTc
MIBI Study
F-18FDG PET Study
Mismatched Matched
Apex 224 99 125
Anterior 179 74 105
Septum 207 108 99
Lateral 82 39 43
Inferior 94 34 60
Total 786 354 432
Table 3 – Segmental involvement and comorbidities.
Matched
segments
Mismatched
segments
p value
Diabetes mellitus
(n = 71)
262 210 0.0685
Hypertension (n = 64) 270 162 0.0005
Both (n = 40) 171 101 0.0043
None (n = 25) 70 84 0.2590
Table depicts distribution of matched and mismatched segments
in patients with diabetes mellitus and hypertension, having both
co-morbidities or having none of it. As depicted, patients with
hypertension or having both co-morbidities, had statistically
signiﬁcantly more matched segments than mismatched segments.
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underwent medical management.
2.4. Echocardiography
Patients underwent echocardiography at the time of PET scans
and 3 months after starting treatment during follow-up,
whether medical or surgical. Echocardiographic images were
obtained in the standard parasternal long, short axes and
apical 4- and 2-chamber views utilizing digital Vivid 7
ultrasound equipment with a combined tissue imaging 2.5–
4.0 MHz transducer. At least three cardiac cycles were
monitored at the LV base, midpapillary muscle level, and
apex for wall motion assessment. Two-dimensional (2D)
ventricular volumes and LV ejection fraction (LVEF) were
measured from the 4- and 2-chamber views using the modiﬁed
Simpson's formula.9 Regional wall motion abnormality
(RWMA) was recorded as normokinesia, hypokinesia, akinesia
or dyskinesia. Patients were considered responding to treat-
ment if there was either increase or no change in LVEF on
follow-up echocardiograms as reported earlier.10,11
2.5. Coronary angiography
All patients had undergone invasive coronary angiography.
Twenty-nine patients had angiography done elsewhere and
were referred for viability study to our hospital. Rest 91
underwent coronary angiography either before or within one
week of myocardial perfusion and FDG PET study. The stenosis
in left anterior descending (LAD), left circumﬂex (LCx), and
right coronary artery (RCA) were noted. The stenosis in their
respective branches were categorized under main artery for
analysis purpose.
2.6. Statistical analysis
Continuous variables were expressed as mean  SD, and all
categorical variables were expressed as percentages. A paired '
t' test was used for intra group comparison and unpaired 't' test
for comparison between two groups. Differences were consid-
ered signiﬁcant at p value <0.05. Pearson's correlation was
used to ﬁnd the relationship between two variables to assess
how strongly they were related to each other. Conﬁdence
intervals (C.I.) were calculated at 95% interval levels.
3. Results
On analysis of coronary artery stenosis distribution, 33 patients
had single vessel disease (SVD) and 48 patients had triple vessel
disease (TVD). Rest of the patients had double vessel disease
(DVD). Most commonly involved artery and its branches in our
study was LAD in 113 patients (94%) followed by RCA in 71
patients (59%) while LCx was involved in 72 patients (60%).
A total of 786 segments of LV myocardium showed reduced
perfusion on 99mTc-MIBI study, most commonly in apex (224),
followed by septum (207), anterior (179), inferior (94) and lateral
walls (82). Matched perfusion defects were seen in 432 segments
(55%) and mismatched perfusion defects were noted in 354 (45%)
segments (Table 2). Patients having DM, HTN or both showedmore number of matched segments (scarred myocardium) than
mismatched segments (viable myocardium); however, this
difference was statistically signiﬁcant in hypertensive patients
(p = 0.0005) and also in patients having both co-morbidities
(p = 0.0043) but not in those with diabetes alone (p = 0.0685).
Patients who did not have any co-morbidities showed more
number of mismatched segments than matched segments,
however this observation was not statistically signiﬁcant
(p = 0.2590) (Table 3).
Echocardiographically, there were 376 hypokinetic, 343
akinetic and 5 dyskinetic segments. In some segments the
echocardiography showed RWMA but the perfusion was
normal and vice versa was also observed. In 33 patients PET
and SPECT study showed myocardial changes in 62 wall
segments whereas echocardiography showed no RWMA. Of
these, 19 patients showed mismatched defects in 29 wall
segments and 14 patients showed matched defects in 33 wall
segments. Similarly in 50 patients, echocardiography showed
RWMA in 67 wall segments with normal perfusion and the
details are as shown in Table 4.
These patients underwent either revascularization or
medical management depending on the ﬁndings on viability
assessment as described previously. Revascularization includ-
ed either stenting or coronary artery bypass graft (CABG)
surgery. Seventy-eight patients with myocardial viability of
more than 7% underwent revascularization and 42 patients
were managed medically as they showed either less than 7%
myocardial viability or non-viable segments.
There was either increase or no change in LVEF in 106
patients (88%) after treatment; of which 73 patients managed
Table 4 – Territory wise viability in various segments
compared to echocardiographic observation.
Territory Mismatched
defects
hibernating
myocardium
Matched
defects
scarred
myocardium
p-Value
LAD
Dyskinetic 0 3 0.128
Akinetic 132 165 0.505
Hypokinetic 135 142 0.617
LCx
Dyskinetic 0 0 N.A.
Akinetic 8 4 0.177
Hypokinetic 29 23 0.111
RCA
Dyskinetic 0 2 N.A.
Akinetic 13 21 0.79
Hypokinetic 18 29 0.525
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32 patients had both diabetes and HTN, while 25 patients did
not have either of it and rest had either diabetes or HTN alone.
Fourteen patients (12%) showed reduction in LVEF, and all
them had either diabetes or HTN or both. The decrease in EF
was not dependant on the number of blood vessels involved as
assessed by coronary angiograms. Of the fourteen patients
(5 managed surgically and 9 managed medically) who showed
reduction in LVEF, six had SVD, four had DVD and four had
TVD.
When comparing surgically managed patients (78 patients)
with medically managed patients (42 patients), the change in
LVEF after management was 3.46  4.5 (C.I. = 2.46–4.46) in
surgical group and 0.71  5.0 (C.I. = 0.79 to 2.21) in medical
group. The increase in LVEF was statistically signiﬁcant for
surgically managed patients (p = 0.002). Only 5 (6.4%) patients
managed surgically showed fall in LVEF while 9 patients
(21.4%) patients managed medically showed fall in LVEF. There
was a weak negative correlation between changes in LVEF and
patients having number of matched segments; however, this
difference was not statistically signiﬁcant (r = 0.268; p = 0.08).
Similarly, there was positive correlation between difference in
LVEF and patients having number of mismatched segments,
which was also not statistically signiﬁcant (r = 0.333; p = 0.39).
The change in LVEF after treatment in patients, who did not
have DM or HTN (n = 25) was 5.0  4.78, which was statistically
signiﬁcant, when compared to patients with DM alone (1.7
 4.92), HTN alone (1.5  4.68) or having both (1.0  4.83).
None of the patients without DM or HTN showed fall in LVEFTable 5 – Change in LVEF in different groups.
Mean LVEF ( p value
compared to none group)
Diabetes mellitus (n = 71) 1.7  4.92 (0.004) 
Hypertension (n = 64) 1.5  4.68 (0.002) 
Both (n = 40) 1.0  4.83 (0.001) 
None (n = 25) 5.0  4.78 (Table 5). Figs. 1 and 2 represent 2 of our patients. Fig. 1 is an
example of a 60-year-old male with severe LV dysfunction,
LAD territory was found viable on PET-CT scan. After LAD
stenting LVEF improved by 10% during 3 months follow-up.
Fig. 2 is an example of two-vessel disease. PET assessment
revealed viability only in LAD territory. Hence CABG was
deferred and only LAD stenting was done. No reduction in
LVEF was noted at 3 months follow-up.
4. Discussion
Viability assessment has become an important investigation
in the management of patients with LV dysfunction, who
present late after MI. This can be done by many imaging
techniques such as 18F-FDG PET-CT, Cardiac MRI, SPECT-CT
imaging, and dobutamine stress echocardiography.12–16 In
general, nuclear imaging techniques have a high sensitivity for
the detection of viability, whereas techniques evaluating
contractile reserve have somewhat lower sensitivity and a
higher speciﬁcity.16 Many potential end points have been
described to measure outcomes after revascularization in
viability studies including improvement in regional LV
function, global LV function, improvement of symptoms,
improvement in exercise capacity and long term prognosis.17
We used global LVEF for follow-up of our patients. Studies have
shown that in patients with ischemic cardiomyopathy with
viable myocardium, LVEF does not always improve after
revascularization,10,11 hence even no change in EF was
considered favorable outcome in our study.
DM and HTN are important independent risk factors in the
development of ischemic CAD. In our study, 79% (n = 95) had
either DM or HTN or both and 21% (n = 25) did not have either of
it. Peterson et al.18 showed that when CAD occurs in diabetics,
it is associated with worse outcomes than in non-diabetics.
Similarly Treasure et al.19 showed that in long standing HTN,
the hypertrophied heart muscle results in impaired vasodila-
tor stimuli and inadequate angiogenesis leading to reduced
number of collaterals, hence more number of scarred
segments. Our study showed similar results, that in patients
having DM or HTN or both, showed less increase in LVEF as
compared to patients who did not have either of it. Patients
with HTN had statistically more number of scarred segments
than viable segments.
Patients of CAD and LV dysfunction showing mismatch
segments on PET study showed poor annual survival with
medical therapy but revascularization in these patients was
associated with improvement in LVEF.20,21 In our study, allChange in LVEF
Decrease Increase No change
12 (16.9%) 26 (36.6%) 33 (46.5%)
11 (17.1%) 20 (31.3%) 33 (51.6%)
8 (20.2%) 11 (27.5%) 21 (52.5%)
0 (0%) 15 (60%) 10 (40%)
Fig. 1 – A 60-year hypertensive male, LVEF 35%. (a) Coronary angiography shows 80% stenosis in proximal LAD. (b) Thrombus
in the distal segment of LAD. (c) Viability assessment showed >95% viability in LAD territory (White arrows). The patient
underwent LAD stenting. His LVEF increased by 10% at 3 months follow-up.
Fig. 2 – A 57-year diabetic and hypertensive male. (a) Coronary angiography shows 80% stenosis in proximal LAD before
bifurcation and 80% stenosis after bifurcation. (b) A long diseased segment in the LCX. (c) Viability assessment showed viable
myocardium in LAD territory (White arrows) while distal LCX showed scarred tissue (White arrowhead). Rest of the LCX
territory showed normal perfusion with no mismatch viability. Hence CABG was deferred and patient underwent LAD
stenting alone and no reduction in LVEF was noted at 3 months follow-up.
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surgical management and of these only 6.4% of patients
showed fall in LVEF as compared to 21.8% of patients who were
managed medically.
The STICH trial22 showed that patients with viable
myocardium had lower overall rates of death than those
without viable myocardium (p = 0.003), however after adjust-
ment for other baseline prognostic variables in a multivariate
model, the pre-speciﬁed viability status was not statistically
signiﬁcant (p = 0.21), thereby concluding that as regards
mortality, viability assessment did not have survival advan-
tage in patients undergoing CABG surgery compared to
medical therapy. However, this study had many drawbacks
such as using SPECT alone for viability assessment, asymp-
tomatic subjects accounted for 40% of patients enrolled and
only 49% of patients underwent careful functional evaluation
pre-randomization. Our study differs from STICH trial in
methodology, use of 18F-FDG PET-CT in viability assessment
and use of LVEF as end point assessment. In our study, we did
not take symptoms or survival as endpoints, and this explains
why our study found viability assessment useful in deciding
management in 40% of our patients.
Haas et al.23 showed that not performing a viability study
before surgical management, resulted in too many high-risk
patients without viability being subjected to surgery resulting
in worse outcomes. To some extent we avoided this situation
as only those patients who showed myocardial viability
underwent revascularization and our result showed that
93.6% showed no decrease in post-revascularization LVEF.
Similarly Dreyfus et al.24 reported that viability assessment
should be part of selection process in patients with low LVEF
for surgical revascularization. We are in agreement with their
views that proper selection of patients based on viability
assessment helps in reducing peri-operative and post-opera-
tive mortality and also improves outcomes.
5. Conclusion
Our study has shown that evidence based viability study can
be used to individualize the management. It helped in deciding
, whether patient should receive surgical or medical treatment
based on viability assessment. This also helped in preventing
unnecessary economic loss to the patient apart from reducing
morbidity. In our opinion the viability study should be
performed in all patients who present 12 h after acute MI
and also in those who present with LV dysfunction due to
ischemic heart disease.
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